Transforming growth factor (TGF)-β expression and activation mechanisms as potential targets for anti-tumor therapy...

Area of Science:

• Oncology
• Molecular Biology
• Drug Development

Background:

• Cancer metastasis is a primary cause of mortality, driving the need for novel therapeutic strategies.
• Transforming growth factor beta (TGF-β) plays a complex, dual role in cancer, promoting invasion and metastasis while also suppressing early tumor progression.
• The narrow therapeutic window for TGF-β targeting presents significant challenges in patient selection and treatment timing.

Purpose of the Study:

• To review current methods for the clinical evaluation of transforming growth factor beta (TGF-β) in cancer invasion and metastasis.
• To discuss the challenges and potential of TGF-β inhibitors in clinical development.
• To highlight the importance of validating evaluation methods for future clinical trials.

Main Methods:

• Review of existing literature on TGF-β inhibitors and clinical evaluation techniques.
• Discussion of methods including ex vivo stimulation assays, TGF-β response signatures, and molecular imaging.
• Emphasis on the need for validation of these methods in clinical settings.

Main Results:

• Several TGF-β inhibitors are in clinical development, targeting TGF-β production, activation, or signaling.
• Challenges remain regarding the specificity and long-term toxicity of TGF-β inhibitors.
• Current clinical evaluation methods require further validation to determine their predictive power.

Conclusions:

• Effective clinical application of TGF-β inhibitors depends on precise patient selection and robust evaluation methods.
• Validated methods are crucial for monitoring TGF-β's role during tumor invasion and metastasis in clinical trials.
• Future research should focus on validating these evaluation techniques to optimize TGF-β-targeted cancer therapies.